Nephrol Dial Transplant (1999) 14: 2455-2460
© 1999 European Renal Association-European Dialysis and Transplant Association
Impaired kidney transplant survival in patients with antibodies to hepatitis C virus
Servicio de Nefrología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
Correspondence and offprint requests to: Dr Miguel A. Gentil, Servicio de Nefrología, Hospital U. Virgen del Rocío, C/ Manuel Siurot s/n, E-41013 Sevilla, Spain.
Background. With a few exceptions, most published studies do not show an influence of antibodies to the hepatitis C virus (HCV) on the success of a kidney transplant.
Methods. We studied all our renal transplant recipients who had received kidneys from cadaver donors (n=335) and had been treated with quadruple immunosuppression (steroids, azathioprine, and antilymphocyte antibodies, followed by cyclosporin). We had information on the status of the hepatitis C antibodies before and/or after the transplant in 320 cases (95.5%; in 300, pre-transplant). Patients with HCV antibodies before and/or after the transplant were considered to be HCV positive (HCV+).
Results. The HCV+ patients had more time in dialysis and a greater number of transfusions, hyperimmunized cases, and re-transplants. The evolution in the first post-transplant year was similar in both groups, but afterwards, the HCV+ patients had proteinuria more often as well as worse kidney function. The survival rate of the graft was significantly less in the HCV+ cases: 90.6, 68.3 and 51.0% at respectively 1, 5 and 10 years, compared with 91.5, 84.7 and 66.5% in HCV- patients (P<0.01). The patient survival rate was: 96.4, 87.0, and 71.9% in the HCV+ patients at 1, 5, and 10 years, compared with 98.2, 96.0 and 90.0% in the HCV- cases respectively (P<0.01). The differences remained the same in stratified studies according to time spent in dialysis or pre/post-transplant evolution of HCV antibodies, even when immunologically high-risk patients were excluded. In multivariant analysis, the presence of HCV antibodies acted as a independent prognostic factor for the survival of the kidney and the patient: 3.0 (1.8–5.0) and 3.1 (1.2–7.8) odds-ratio (95% of the confidence interval), respectively. The main cause of death among HCV+ patients was cardiovascular; there was no apparent increase in mortality rate due to infections or chronic liver disease. The loss of organs was mainly due to chronic nephropathy or death with a functioning kidney.
Conclusion. The presence of hepatitis C antibodies, before or after transplantation, is associated with a worse long-term survival rate for both the patient and the transplanted kidney in our patients treated with quadruple therapy.
Keywords: acute transplant rejection; chronic liver disease; chronic renal failure; hepatitis C; kidney transplantation; survival
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. P. Forman, N. Tolkoff-Rubin, M. Pascual, and J. Lin Hepatitis C, Acute Humoral Rejection, and Renal Allograft Survival J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3249 - 3255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Espinosa, A. Martin-Malo, M. A. A. de Lara, and P. Aljama Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients Nephrol. Dial. Transplant., August 1, 2001; 16(8): 1669 - 1674. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. MORALES and J. M. CAMPISTOL Transplantation in the Patient with Hepatitis C J. Am. Soc. Nephrol., July 1, 2000; 11(7): 1343 - 1353. [Full Text]
|
|